ForPatients
by Roche

Alzheimer's Disease (AD)

A study of a new medicine (semorinemab) in patients with moderate Alzheimer's disease

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

Trial Status	Trial Runs In	Trial Identifier
Completed	4 Countries	NCT03828747 GN40040

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period. There may be up to two study cohorts.

Genentech, Inc. Sponsor	**Phase 2** Phase

NCT03828747 GN40040
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=50 Years & <= 85 Years	No

© 2022 F. Hoffmann-La Roche Ltd